Teladoc Health Inc のコンセンサス目標株価は $14.28 で、28 人のアナリストの評価に基づいています。最高値は $37(1 19, 2023 に Oppenheimer が発表)、最安値は $7(5 28, 2025 に B of A Securities が発表)です。直近のアナリスト評価 3 件は Evercore ISI Group、Citigroup、Evercore ISI Group により 10 30, 2025、10 21, 2025、10 8, 2025 に発表されました。Evercore ISI Group、Citigroup、Evercore ISI Group の平均目標株価は $9.17 で、これらの最新評価から Teladoc Health Inc に対して 21.57% のupsideが示唆されています。
1アナリスト評価から算出
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/30/2025 | 6.1% | Evercore ISI Group | $9 → $8 | Maintains | In-Line | |||
10/21/2025 | 39.25% | Citigroup | $9.5 → $10.5 | Maintains | Neutral | |||
10/08/2025 | 19.36% | Evercore ISI Group | $8 → $9 | Maintains | In-Line | |||
07/25/2025 | 32.62% | Mizuho | → $10 | Initiates | → Neutral | |||
07/09/2025 | 6.1% | Evercore ISI Group | $7 → $8 | Maintains | In-Line | |||
05/28/2025 | -7.16% | B of A Securities | $8 → $7 | Maintains | Neutral | |||
05/27/2025 | 19.36% | Truist Securities | $10 → $9 | Maintains | Hold | |||
05/08/2025 | 6.1% | Wells Fargo | $10 → $8 | Maintains | Equal-Weight | |||
05/01/2025 | 59.15% | Canaccord Genuity | $14 → $12 | Maintains | Buy | |||
05/01/2025 | 32.62% | Goldman Sachs | $13 → $10 | Maintains | Buy | |||
05/01/2025 | 6.1% | Stifel | $9 → $8 | Maintains | Hold | |||
05/01/2025 | -7.16% | Evercore ISI Group | $8 → $7 | Maintains | In-Line | |||
05/01/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
04/25/2025 | 16.04% | Citigroup | $11 → $8.75 | Maintains | Neutral | |||
04/21/2025 | 6.1% | Jefferies | $10 → $8 | Maintains | Hold | |||
04/11/2025 | 6.1% | B of A Securities | $9.5 → $8 | Maintains | Neutral | |||
03/03/2025 | 72.41% | Goldman Sachs | $16 → $13 | Maintains | Buy | |||
02/27/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
02/27/2025 | 59.15% | Piper Sandler | $13 → $12 | Maintains | Overweight | |||
02/18/2025 | 112.2% | Goldman Sachs | $14 → $16 | Maintains | Buy | |||
02/12/2025 | 79.04% | B of A Securities | $11.5 → $13.5 | Maintains | Neutral | |||
02/06/2025 | 52.52% | B of A Securities | $10.5 → $11.5 | Maintains | Neutral | |||
01/24/2025 | 59.15% | RBC Capital | $11 → $12 | Maintains | Outperform | |||
01/24/2025 | 59.15% | Oppenheimer | $14 → $12 | Maintains | Outperform | |||
12/04/2024 | 72.41% | Piper Sandler | $11 → $13 | Reiterates | Overweight → Overweight | |||
11/15/2024 | 85.67% | Goldman Sachs | → $14 | Initiates | → Buy | |||
11/01/2024 | 59.15% | Deutsche Bank | $10 → $12 | Maintains | Hold | |||
10/31/2024 | 59.15% | Barclays | $10 → $12 | Maintains | Overweight | |||
10/31/2024 | 6.1% | TD Cowen | $9 → $8 | Maintains | Hold | |||
10/09/2024 | 32.62% | RBC Capital | $9 → $10 | Maintains | Outperform | |||
10/08/2024 | 19.36% | Evercore ISI Group | $8 → $9 | Maintains | In-Line | |||
09/17/2024 | 32.62% | Jefferies | $8 → $10 | Maintains | Hold | |||
08/26/2024 | 19.36% | JP Morgan | $16 → $9 | Maintains | Neutral | |||
08/20/2024 | 32.62% | Cantor Fitzgerald | $10 → $10 | Reiterates | Overweight → Overweight | |||
08/06/2024 | 32.62% | Piper Sandler | $25 → $10 | Maintains | Overweight | |||
08/02/2024 | 32.62% | Deutsche Bank | $15 → $10 | Maintains | Hold | |||
08/02/2024 | 32.62% | Truist Securities | $15 → $10 | Maintains | Hold | |||
08/01/2024 | — | Needham | — | Reiterates | → Hold | |||
08/01/2024 | 19.36% | TD Cowen | $15 → $9 | Maintains | Hold | |||
08/01/2024 | 19.36% | RBC Capital | $18 → $9 | Maintains | Outperform | |||
08/01/2024 | 32.62% | Barclays | $20 → $10 | Maintains | Overweight | |||
08/01/2024 | 19.36% | Stifel | $16 → $9 | Maintains | Hold | |||
08/01/2024 | 6.1% | DA Davidson | $12 → $8 | Maintains | Neutral | |||
08/01/2024 | 125.46% | Canaccord Genuity | $25 → $17 | Maintains | Buy | |||
08/01/2024 | 125.46% | Oppenheimer | $21 → $17 | Maintains | Outperform | |||
07/09/2024 | 32.62% | Evercore ISI Group | $14 → $10 | Maintains | In-Line | |||
05/21/2024 | 112.2% | JP Morgan | $19 → $16 | Maintains | Neutral | |||
05/20/2024 | 85.67% | Jefferies | $16 → $14 | Maintains | Hold | |||
05/14/2024 | 79.04% | B of A Securities | $16.5 → $13.5 | Maintains | Neutral | |||
04/29/2024 | 98.93% | Wells Fargo | $17 → $15 | Maintains | Equal-Weight | |||
04/26/2024 | 178.51% | Oppenheimer | $26 → $21 | Maintains | Outperform | |||
04/26/2024 | 98.93% | TD Cowen | $16 → $15 | Maintains | Hold | |||
04/26/2024 | 85.67% | Evercore ISI Group | — | $15 → $14 | Maintains | In-Line | ||
04/26/2024 | 138.72% | RBC Capital | $25 → $18 | Maintains | Outperform | |||
04/26/2024 | 112.2% | Stifel | $21 → $16 | Maintains | Hold | |||
04/26/2024 | 165.24% | Barclays | $25 → $20 | Maintains | Overweight | |||
04/26/2024 | 231.56% | Canaccord Genuity | $28 → $25 | Maintains | Buy | |||
04/26/2024 | — | Needham | — | Reiterates | → Hold | |||
04/05/2024 | — | Needham | — | Reiterates | → Hold | |||
03/06/2024 | 125.46% | Truist Securities | $23 → $17 | Maintains | Hold | |||
02/29/2024 | 191.77% | Cantor Fitzgerald | → $22 | Initiates | → Overweight | |||
02/26/2024 | 125.46% | Leerink Partners | → $17 | Initiates | → Market Perform | |||
02/21/2024 | 138.72% | DA Davidson | $22 → $18 | Maintains | Neutral | |||
02/21/2024 | 151.98% | Citigroup | $21 → $19 | Maintains | Neutral | |||
02/21/2024 | 231.56% | RBC Capital | $30 → $25 | Maintains | Outperform | |||
02/21/2024 | 231.56% | Barclays | $26 → $25 | Maintains | Overweight | |||
02/21/2024 | 231.56% | Piper Sandler | $30 → $25 | Maintains | Overweight | |||
02/21/2024 | 271.34% | Canaccord Genuity | $34 → $28 | Maintains | Buy | |||
11/17/2023 | 151.98% | JP Morgan | $33 → $19 | Maintains | Neutral | |||
10/25/2023 | 297.87% | RBC Capital | $35 → $30 | Maintains | Outperform | |||
10/25/2023 | 244.82% | Oppenheimer | $35 → $26 | Maintains | Outperform | |||
10/23/2023 | 178.51% | Citigroup | $29 → $21 | Maintains | Neutral | |||
10/20/2023 | 178.51% | Citigroup | $29 → $21 | Maintains | Neutral | |||
09/25/2023 | 271.34% | Truist Securities | → $28 | Reiterates | Hold → Hold | |||
07/26/2023 | 271.34% | Stephens & Co. | → $28 | Reiterates | Equal-Weight → Equal-Weight | |||
07/26/2023 | 364.18% | RBC Capital | → $35 | Reiterates | Outperform → Outperform | |||
07/26/2023 | 284.61% | Citigroup | $31 → $29 | Maintains | Neutral | |||
07/26/2023 | 258.08% | Credit Suisse | → $27 | Reiterates | Neutral → Neutral | |||
04/28/2023 | 284.61% | Deutsche Bank | $27 → $29 | Maintains | Hold | |||
04/27/2023 | 311.13% | Citigroup | $30 → $31 | Maintains | Neutral | |||
04/27/2023 | 364.18% | RBC Capital | → $35 | Reiterates | → Outperform | |||
04/27/2023 | 258.08% | Credit Suisse | → $27 | Reiterates | → Neutral | |||
04/27/2023 | 284.61% | Barclays | $28 → $29 | Maintains | Equal-Weight | |||
04/12/2023 | 231.56% | Stephens & Co. | → $25 | Initiates | → Equal-Weight | |||
03/10/2023 | 258.08% | Credit Suisse | $30 → $27 | Maintains | Neutral | |||
03/06/2023 | 377.44% | Canaccord Genuity | $40 → $36 | Maintains | Buy | |||
03/06/2023 | 205.03% | Wells Fargo | $28 → $23 | Maintains | Equal-Weight | |||
02/28/2023 | 297.87% | Citigroup | $33 → $30 | Maintains | Neutral | |||
02/27/2023 | 258.08% | Deutsche Bank | $31 → $27 | Maintains | Hold | |||
02/27/2023 | 337.65% | JP Morgan | $35 → $33 | Maintains | Neutral | |||
02/23/2023 | 364.18% | Oppenheimer | $37 → $35 | Maintains | Outperform | |||
02/23/2023 | 364.18% | RBC Capital | → $35 | Reiterates | → Outperform | |||
02/23/2023 | 350.92% | SVB Leerink | → $34 | Upgrade | Market Perform → Outperform | |||
01/19/2023 | 390.7% | Oppenheimer | $45 → $37 | Maintains | Outperform | |||
01/18/2023 | 271.34% | Barclays | $32 → $28 | Maintains | Equal-Weight | |||
12/13/2022 | 337.65% | Citigroup | $36 → $33 | Maintains | Neutral |
Teladoc Healthの最新目標株価Teladoc Health。(NYSE:TDOC) の最新目標株価をEvercore ISI Groupが10 30, 2025日に発表した。このアナリスト会社はTeladoc Health ({{change}:{{mbol}}) {{{quoteName}}の{{change}:{{symbol}}からriseまで12ヶ月以内(6.10% upsideの可能性あり)と予想する$8.00の目標株価を設定しました。過去1年間に26のアナリスト会社がレーティングを報告しています。
Teladoc Healthの最新のアナリストレーティングはTeladoc Healthです。(NYSE:TDOC) の最新のアナリストレーティングはEvercore ISI Groupによるもので、Teladoc HealthのTeladoc Healthです。{actionCompany}}のin-line評価です。
Teladoc Health Incの最後のアップグレードは2 23, 2023日に行われ、SVB Leerinkは目標株価を$34に引き上げました。companyName}}のSVB Leerinkの以前のa market performは$34でした。
Teladoc Healthの最後のダウングレードはありません。
アナリストは、公開財務諸表を調べたり、Teladoc Healthの役員や顧客に話を聞いたり、決算の電話会議を傍聴したりと、広範な調査を行った上で株価の格付けを行っています。ほとんどのアナリストは3ヶ月ごとにこの作業を行いますので、毎年1社につき4つの格付けを得ることになります。companyName}}の最終レーティングは10 30, 2025日に提出されましたので、次のレーティングは10 30, 2026日あたりに提出されるものと思われます。
レーティングは主観的なものであり変化しますが、最新のTeladoc Health (TDOC) (TDOC) のレーティングは維持で、目標株価は$9.00から$8.00でした。現在の価格 Teladoc Health ({{exchange}}) (TDOC) の現在の取引価格は$7.54で、これはアナリストの予測レンジout ofです。
ブラウズ アナリスト評価と目標株価 全銘柄の
